Voxzogo demonstrates positive results for infants with dwarfism
Biomarin’s achondroplasia treatment has been approved for children as young as five in the US, and the firm is now hoping to address patients who have yet to turn one.
by christian bundgaard, translated by daniel pedersen
In November 2021, the US Food and Drug Administration (FDA) market approved Biomarin’s drug, Voxzogo (vosoritide), for five-year-old children and up who have achondroplasia, also known as dwarfism.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin raises Voxzogo sales expectations again
For subscribers
Biomarin projects 2022 Voxzogo sales of USD 115m
For subscribers
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers
